Liquidity and Capital Resources	9 Months Ended
Sep. 30, 2017
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	10. Liquidity and Capital Resources At September 30, 2017, the Company had cash and cash equivalents of approximately $46.0 million. Management believes that our current cash and cash equivalents will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2017 and the first ten months of 2018 of approximately $32.6 million, which includes approximately $5.5 million for our clinical programs for aldoxorubicin, approximately $4.1 million for the research and clinical development of novel anti-cancer drug candidates at our Freiburg operations, approximately $0.8 million for general operation of our clinical programs, approximately $8.3 million for other general and administrative expenses, and approximately $13.7 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections. If our licensing partner obtains marketing approval and successfully commercializes aldoxorubicin, we anticipate it could take several years, for it to generate significant recurring revenue. We will be dependent on future financing and possible other strategic partnerships until such time, if ever, as it can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourself, or seek to sell some or all of our assets or merge with or be acquired by another company.

10. Liquidity and Capital Resources

At September 30, 2017, the Company had cash and cash equivalents of approximately $46.0 million. Management believes that our current cash and cash equivalents will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2017 and the first ten months of 2018 of approximately $32.6 million, which includes approximately $5.5 million for our clinical programs for aldoxorubicin, approximately $4.1 million for the research and clinical development of novel anti-cancer drug candidates at our Freiburg operations, approximately $0.8 million for general operation of our clinical programs, approximately $8.3 million for other general and administrative expenses, and approximately $13.7 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

If our licensing partner obtains marketing approval and successfully commercializes aldoxorubicin, we anticipate it could take several years, for it to generate significant recurring revenue. We will be dependent on future financing and possible other strategic partnerships until such time, if ever, as it can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourself, or seek to sell some or all of our assets or merge with or be acquired by another company.